Xbryk FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 30, 2026.
FDA Approved: Yes (First approved February 13, 2025)
Brand name: Xbryk
Generic name: denosumab-dssb
Dosage form: Injection
Company: Samsung Bioepis Co., Ltd.
Treatment for: Osteolytic Bone Lesions of Multiple Myeloma, Osteolytic Bone Metastases of Solid Tumors, Giant Cell Tumor of Bone, Hypercalcemia of Malignancy
Add Drugs.com as a trusted source on Google to see more of our health news and information in your Google Search results.
- Tap the button to open Google's source settings.
- Tick the box next to Drugs.com.
- You can change it anytime in your Google settings.
Requires a signed-in Google account.
Xbryk (denosumab-dssb) is a RANK ligand (RANKL) inhibitor biosimilar to Xgeva (denosumab) for use in the prevention of skeletal-related events in patients with multiple myeloma or bone metastases from solid tumors, treatment of giant cell tumor of bone, and treatment of hypercalcemia of malignancy.
- Xbryk is indicated for:
- prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
- treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
- treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. - Xbryk is approved in the following presentation:
Product Presentation Strength Biosimilar / Interchangeable Single-Dose Vial (Subcutaneous Injection) 120 mg/1.7 mL (70 mg/mL) Interchangeable - Xbryk is administered via subcutaneous injection.
- FDA approval of Xbryk was based on totality of evidence including analytical, non-clinical data, and clinical data that demonstrated that Xbryk is biosimilar to Xgeva.
- Warnings and precautions associated with Xbryk include hypersensitivity reactions, hypocalcemia, osteonecrosis of the jaw, atypical femoral fracture, hypercalcemia following treatment discontinuation in patients with giant cell tumor of bone and in patients with growing skeletons, and multiple vertebral fractures following treatment discontinuation.
- Common adverse reactions:
- Bone Metastasis from Solid Tumors: Common adverse reactions include fatigue/asthenia, hypophosphatemia, and nausea.
- Multiple Myeloma: Common adverse reactions include diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache.
- Giant Cell Tumor of Bone: Common adverse reactions include arthralgia, headache, nausea, back pain, fatigue, and pain in extremity.
- Hypercalcemia of Malignancy: Common adverse reactions include nausea, dyspnea, decreased appetite, headache, peripheral edema, vomiting, anemia, constipation, and diarrhea. - Xbryk is the second FDA-approved biosimilar to Xgeva (denosumab).
Brand Name Generic Name Date of Approval Wyost denosumab-bbdz March 5, 2024 Xbryk denosumab-dssb February 13, 2025 Osenvelt denosumab-bmwo February 28, 2025 Bomyntra denosumab-bnht March 25, 2025 Bilprevda denosumab-nxxp August 29, 2025 Aukelso denosumab-kyqq September 16, 2025 Xtrenbo denosumab-qbde September 26, 2025 Jubereq denosumab-desu October 29, 2025 Oziltus denosumab-mobz December 19, 2025 Degevma denosumab-adet September 25, 2026 - Ospomyv (denosumab-dssb) was also approved on February 13, 2025 as the second biosimilar to Prolia (denosumab).
Development timeline for Xbryk
| Date | Article |
|---|---|
| Feb 16, 2025 | Approval FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.